BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Newcastle Hospitals Clinical Skills Academy - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://skillsacademy.newcastle-hospitals.nhs.uk
X-WR-CALDESC:Events for Newcastle Hospitals Clinical Skills Academy
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20241127T093000
DTEND;TZID=Europe/London:20241127T123000
DTSTAMP:20260407T083652
CREATED:20241001T075411Z
LAST-MODIFIED:20250429T143940Z
UID:10000089-1732699800-1732710600@skillsacademy.newcastle-hospitals.nhs.uk
SUMMARY:Novel Immunotherapies for Solid Tumours - November 2024
DESCRIPTION:An introduction to progress made in developing novel immunotherapies for solid tumours (excluding immune checkpoint inhibitors). \nOverview\nThis course emphasises the progress made in developing novel immunotherapies for solid tumours\, such as CAR T cell therapy\, TCR-engineered T cell therapy\, tumour infiltrating lymphocytes\, T cell engagers\, and vaccine-based treatments. \nOver the course of one morning\, Dr Elaine Vickers – a leading independent educator on the science of new cancer treatments – discusses novel approaches that may have a future as standard treatments for solid tumours including features of solid tumours that provoke the immune system and those that allow cancer cells to survive and thrive. \nElaine will describe cancers where novel immunotherapies are being most intensively explored\, such as in the treatment of: \n\ncancers already known to be sensitive to immunotherapy\, such as melanoma skin cancer\ncancers where new treatments are desperately needed\, such as pancreatic cancer and glioblastoma\ncancers where a particularly promising target has been identified\, such as Claudin 18.2 in stomach cancer and other GI cancers.\n\nIn the second session of the morning\, Elaine focuses on cell-based immunotherapies such as TIL (tumour infiltrating lymphocyte) therapy\, CAR T cell therapy\, and TCR-engineered T cell therapy. She explains why we haven’t made more progress with these treatments and explores how this might change in the future. \nIn the final session\, Elaine will examine some of the most innovative and exciting immunotherapies being developed\, including T cell engagers and mRNA vaccines. \nAudience\nThis content is ideal for research nurses\, clinical nurse specialists\, pharmacists\, and clinical trials coordinators. It may also interest other healthcare professionals wanting to improve their understanding of immunotherapy. \nAttendance on Elaine’s other course: A Beginner’s Guide to Cancer Immunotherapy would be ideal preparation for this course. \nAs ever\, Elaine will use colourful illustrations and jargon-free explanations to help learners gain a broad understanding of the concepts covered. \nCourse delivery\nThe course delivery date is Wednesday 27th November 2024 and is to be delivered online via Microsoft Teams as follows: \n9.30am – Introduction to novel immunotherapies for solid tumours \n\nThe cancer-immunity cycle\nWhy not every cancer is sensitive to immunotherapy; exploring ‘Hot’\, ‘Cold’\, ‘Immune-suppressed’ and ‘Immune-excluded’ cancers\nHow cancer’s relationship with the immune system differs in different cancer types and the mechanisms that drive this\nIntroducing the cancers in which novel immunotherapies are being explored\n\nQ&A/break \n10.30am – Progress in cell-based immunotherapy for solid tumours \n\nWhere it started: TIL (tumour infiltrating lymphocyte) therapy\nIntroduction to CAR T cell therapy\nCAR proteins and their targets\nWhy don’t we have CAR T cell therapies for solid tumours?\nAn alternative approach: TCR-engineered T cells\n\nQ&A/break \n11.30am – Treatment vaccines\, T cell engagers and other novel approaches in trials \n\nVaccine-based immunotherapy – the general idea and the multitude of approaches being investigated\nPromising results from mRNA vaccine trials\nTebentafusp and tarlatamab – the first T cell engagers approved for solid tumours\nImmunotherapies that leverage macrophages and NK cells\n\nQ&A \n12.30pm – close \nCourse lead\nDr Elaine Vickers PhD of Science Communicated Ltd\nDr Elaine Vickers\, PhD of Science Communicated Ltd has worked as a cancer educator for over twenty years and has previously acted as science communicator for three of the UK’s leading medical research charities\, including four years in the Science Information team at Cancer Research UK. \nElaine is passionate about demystifying the science behind cancer biology and the latest cancer treatments such as kinase inhibitors\, monoclonal antibodies and immunotherapies. \nShe is experienced in teaching people with any level of scientific or medical knowledge from cancer patients through to medical oncologists translating complex and often overwhelming topics into easily digestible and understandable knowledge\, using colourful illustrations to explain scientific concepts. \nThe second edition of her book\, A Beginner’s Guide to Targeted Cancer Treatments – commended by the British Medical Association book awards – is due out by the end of 2024. \nBooking\nTo book a place on this course go to Tickets at the bottom of the page. \nAt checkout you can make an online card payment or enter a coupon code to make alternative payment arrangements. \nAlternative payment arrangements include: \n\nrequesting an invoice (INVOICE)\,\nThe Newcastle upon Tyne Hospitals NHS Foundation Trust staff internal funding (NUTH) – you will need to complete a Trust study leave form.\n\nPlease see the Making payments & Coupons sections of the Help and FAQs.
URL:https://skillsacademy.newcastle-hospitals.nhs.uk/course/novel-immunotherapies-for-solid-tumours-november-2024-2/
LOCATION:Virtual delivery via MS Teams
ATTACH;FMTTYPE=image/jpeg:https://skillsacademy.newcastle-hospitals.nhs.uk/wp-content/uploads/2023/10/MicrosoftTeams-image.jpg
ORGANIZER;CN="Newcastle Hospitals Skills Academy":MAILTO:nuth.newcastlehospitalsskillsacademy@nhs.net
END:VEVENT
END:VCALENDAR